Rozrolimupab: Final Phase II data

Previously reported data from a dose-escalation, open-label, international Phase II trial of rozrolimupab in 61 RhD-positive, non-splenectomized patients with ITP

Read the full 202 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE